Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Management of immune-related adverse events and kinetics of response with ipilimumab.
- J. Weber, K. Kähler, A. Hauschild
- MedicineJournal of clinical oncology : official journal…
- 20 July 2012
A detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy are provided.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
- G. Long, D. Stroyakovskiy, K. Flaherty
- Medicine, BiologyThe New England journal of medicine
- 12 November 2014
A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
- A. Eggermont, V. Chiarion-Sileni, A. Testori
- MedicineThe New England journal of medicine
- 7 October 2016
As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.